eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis

Company Overview

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: $0.00 to $0.05
• 52-Week Range: $0.00 to $17.90
• Volume: 8,317 shs
• Average Volume: 16,095 shs
• Market Capitalization: $940.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.00
• Consensus Rating: Buy

eFFECTOR Therapeutics Stock Analysis - MarketRank™

eFFECTOR Therapeutics scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

eFFECTOR Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

eFFECTOR Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of eFFECTOR Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of eFFECTOR Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for EFTR.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

eFFECTOR Therapeutics does not currently pay a dividend.

Dividend Growth

eFFECTOR Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for EFTR.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: N/A

News Sentiment

eFFECTOR Therapeutics has a news sentiment score of -1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

MarketBeat Follows

1 people have added eFFECTOR Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, eFFECTOR Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.70% of the stock of eFFECTOR Therapeutics is held by insiders.

Percentage Held by Institutions

57.67% of the stock of eFFECTOR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EFTR Stock Analysis - Frequently Asked Questions

How have EFTR shares performed this year?

eFFECTOR Therapeutics' stock was trading at $11.6850 on January 1st, 2024. Since then, EFTR stock has decreased by 100.0% and is now trading at $0.0002.
View the best growth stocks for 2024 here.

How were eFFECTOR Therapeutics' earnings last quarter?

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) announced its quarterly earnings data on Monday, November, 8th. The company reported $10.50 earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.50) by $17.00. The firm had revenue of $0.43 million for the quarter.

When did eFFECTOR Therapeutics' stock split?

eFFECTOR Therapeutics shares reverse split on the morning of Friday, January 12th 2024. The 1-25 reverse split was announced on Friday, January 12th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of eFFECTOR Therapeutics?

Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of eFFECTOR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that eFFECTOR Therapeutics investors own include HubSpot (HUBS), Netflix (NFLX), Tesla (TSLA), Domino's Pizza (DPZ), Athenex (ATNX), ForgeRock (FORG) and Plug Power (PLUG).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EFTR
• CUSIP: N/A
• CIK: 1828522
• Web: www.locustwalkacquisitioncorp.com
• Phone: 858-925-8215
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $24.00
• High Stock Price Target: $24.00
• Low Stock Price Target: $24.00
• Potential Upside/Downside: +11,999,900.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($13.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-35,810,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -146.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.03
• Quick Ratio: 1.03

Sales & Book Value

• Annual Sales: $3.55 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.94) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 4,704,000
• Free Float: 4,483,000
• Market Cap: $940.80
• Optionable: No Data
• Beta: 0.81